Integrin alpha-V Antibodies

Integrin alpha-V (ITGAV)

The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands.

ITGAV:ITGB3 binds to NRG1 (through EGF domain name ) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324).

Gene Information

Human
Gene Name:	ITGAV
Uniprot:	P06756
Entrez:	3685

Family

Belongs to:
integrin alpha chain family

Alternative Names

CD51; Integrin alpha V beta 5; integrin subunit alpha V; ITGAV; MSK8; VNRA; VTNR

Molecular Weight

Mass (kDA):
116.038 kDA

Genomic Context

Human
Location:	2q32.1
Sequence:	2; NC_000002.12 (186590056..186680902)

Subcellular Localizations

Cell membrane; Single-pass type I membrane protein. Cell junction, focal adhesion.

Diseases

• Neoplasms
• Tissue Adhesions
• Malignant Neoplasms
• Tumor Angiogenesis
• Cell Invasion
• Carcinoma
• Neoplasm Metastasis
• Rheumatoid Arthritis
• Arthritis
• Metastatic Malignant Neoplasm To The Lymph Node
• Cell Transformation, Neoplastic
• Melanoma

• Malignant Neoplasm Of Breast
• Hepatitis B
• Neoplasm Invasiveness
• Mammary Neoplasms
• Osteoporosis
• Liver Carcinoma
• Hepatitis

Interacting Proteins

• ITGB3
• ITGB5
• ITGB6

Pathways

• Angiogenesis
• Cell Adhesion
• Cell Proliferation
• Cell Cycle
• Cell-matrix Adhesion
• Integrin Activation
• Pathogenesis
• Osteoblast Differentiation
• Tube Formation
• Immune Response
• Vasculogenesis
• Embryo Development
• Platelet Aggregation

• Blastocyst Formation
• Cholesterol Efflux
• Innate Immune Response
• Cell Differentiation
• Focal Adhesion Assembly
• Gastrulation
• Cell Development

PTMs

• Phosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/ITGAV

Best Uses Of The ITGAV Marker

ITGAV is a biomarker for prostate cancer that can be used to distinguish PCa from benign protostatic hyperplasia. ITGAV is detectable using Western Blot and Boster's ELISA. This article provides an explanation of how ITGAV operates, and how you can make use of it. This article also describes how ITGAV can be used for PCa research.

ITGAV is a biomarker that is used in office for prostate cancer.

In this study, ITGAV was identified in the urinary tract of patients suffering from prostate cancer. These patients had PSA levels above 4 mg/ml. Urine samples were collected prior to surgery. The results showed that ITGAV levels were significantly higher in prostate cancer patients than BPH patients. Further, these findings confirm the notion that urinary ITGAV could be a biomarker of prostate cancer.

One study investigated the diagnostic value of ITGAV, a protein that is found within the prostate cancer patients' urine. patients and predicting benign diagnosis in 56% of. It was discovered that ITGAV levels do not correlate with serum PSA or combined Gleason scores. However, this does not mean that ITGAV levels should be left unnoticed. This test has a lot of promise for diagnosing prostate cancer.

In the study, the ITGAV protein was found in urine samples of healthy men who had PCa. The protein was also detected in patients suffering from BPH and PCa. Western Blotting was employed to analyze urine samples. Anti-ITGAV antibodies were utilized as controls. The study suggests that lower levels of ITGAV may be the result of ITGAV proteolysis.

To further assess the clinical significance of ITGAV, scientists used PCa cell lines and the corresponding anti-ITGAV antibodies. They found that ITGAV was more prominently expressed in PCa cells, compared to BPH cells. Both BPH and cancer cells had low levels of this protein. The study showed statistically significant reductions in ITGAV expression among prostate cancer patients.

It can distinguish between PCa and BPH

There is an urgent need for more precise methods to detect PCa in males, as the early detection of risk factors can reduce the overdiagnosis of PCa, decrease the need for testing and reduce the financial burden on healthcare providers. Biomarkers, like PSA measurement, could be a helpful tool in improving PCa diagnosis. The review of biomarkers highlights the importance of evaluating the results of biomarker studies.

PSA density (or PSA concentration per prostate volume) is a valuable diagnostic tool that helps distinguish PCa patients from those with benign conditions like BPH. While the connection between PSA density and PCa is well-established the study was conducted to determine the most effective cutoff for PCa detection. However, it is to be noted that PSA density is not a 100% reliable diagnostic tool and requires the expertise of a medical professional to interpret the results.

The technique also employs texture analysis to distinguish PCa from BPH. Certain parameters, like the kurtosis and median, were found to be significantly different between PCa and BPH. The 5th percentile of T2W images was significantly different from the median. These results suggest that ADC maps can differentiate between PCa or BPH. Physicians can use the ADC map to determine if a patient suffers from PCa or BPH.

It can be measured using Western blot

The antibody should be directed to the ITGAV's code sequence when taking measurements of ITGAV using Western blot. The antibody is not specific to ITGAV itself. ITGAV is also known as ITGA5 and inhibits cell proliferation. A defect in this gene can result in cell death. This protein is essential to the proper functioning of the immune system. It is essential for prevention of many ailments.

In addition to ITGAV In addition, AY is important in determining the sensitivity of an antigen. The AY mRNA levels in HepG2 cells were two times higher that in adjacent NT cells. ITGAV expression levels were decreased in five of the 17 HCC samples that showed lower AY levels. Pearson Chi-square (kh2) test results also showed significant correlation between ITGAV expression levels and levels of AY. Similar findings were also observed when analyzing data from TCGA.

In addition, the expression of the YY1 as well as ITGB1 was also decreased. These results support the idea that these proteins play a role in transcription in the progression of CRC. This hypothesis is yet to be confirmed. In this study the poor prognosis of patients was associated with ITGAV and ITGB1 in patients with CRC. Although this association is not conclusive, these data suggest that ITGB1 and ITGAV are involved in the early stages of colon cancer metastasis to the liver.

It can be detected using ELISA

There are several ways to find ITGAV and other proteins in samples, such as ELISA. A primary-secondary-ABC system uses avidins conjugated to signal molecules such as Horseradish Peroxide, HRP, to locate proteins of interest. This method is sensitive and precise, with a low background. Other detection methods apart from polysaccharides and avidins make use of organic polymers and polysaccharides. Boster Bio's Super Vision Detection Kits offer an innovative approach to detection.

ITGA5BlxAV is a bispecific antigen against a5b1, was created. SDS-PAGE verified the quality. Flow cytometric binding tests were conducted using monoclonal a5 and alpha–V antibodies, as well as the bispecific ITGA5BlxAV. Bispecific binding was highly associated with total integrin a5 as well as alpha-V binding in multiple cell lines.

The ITGA5BlxAV is an antibody that is able to block endothelial migratory and adhesion. The antibodies' powerful effect on the Integrin a5 Integrins suggests that they target a pathological mechanism. Both ITGA5BlxAV and a monospecific antibody are superior.

It is a useful component in a variety biological assays

The ITGAV gene can be found throughout the body including the prostate. Urine samples are commonly used to measure the circulating ITGAV levels. It is a biomarker for prostate cancer. Numerous studies have demonstrated that urinary ITGAV levels can distinguish between BPH and PCa in 56% of cases. This test could decrease the need to perform unnecessary biopsies for PCa diagnoses.

ITGAV is composed of an transmembrane-protein with a size of 116kDa. Different companies developed antibodies against this protein that allowed researchers to detect bands with molecular weights of 130-140kDa. These antibodies can be used to determine the concentration of ITGAV protein in cell lysates or serum. The polyclonal antibodies bind the receptor at specific locations and, in turn, determine the presence of ITGAV protein.

ITGAV was first observed in LnCap cells lysates and then clonal antibodies were employed to detect the protein in media that had been conditioned. Cloud Clone Corp. and MyBioSource provided antibodies against this integrin. Both A and B panels display MW markers of 100 and 130 kDa. These markers serve as loading controls and were used to detect the levels of ITGAV in the samples.

It is known that the ITGAV gene encodes the integrin alpha (V) beta 3. In reality this receptor has been linked to tumor Neoangiogenesis. Additionally, it has been involved in metastasis and growth of tumors. Furthermore, a polymorphism of the Integrin-alpha-V gene has been associated with RA susceptibility loci.

It is available through Boster Bio

If you're looking for an antibody that is specific to Integrin beta-3, you've come to the right location. The Boster Bio Anti-Integrin alpha V/ITGAV Antibody is available in both WB and flow Cytometry applications. It reacts with the fibrinogen chain sequence H-L–G–G–A–K–D and has been tested on mouse, human, and rat samples.

Recent research revealed that ITGAV was highly predictive of the progression and development of prostate cancer. It had a 91.5 percent specificity and 91.5 percent sensitivities. It also had a larger area under the ROC curve than the serum PSA. This makes it an exciting non-invasive biomarker to be widely employed. You can order ITGAV from Boster Bio today!